New Real-World Data Program for Personalized Oncology Care Revealed by Tempus

October 28, 2022

The artificial intelligence (AI) company Tempus has announced its new precision medicine oncology real-world data (RWD) platform Tempus+. The program is a collaboration between several cancer centers across the US. Over five million electronic health records (EHR) will be organized and made available to researchers through Tempus’ existing Lens software platform.

According to Noah Federman, MD, Professor and Director of the UCLA Pediatric Sarcoma Program, “”With more readily available next-generation sequencing and other molecular profiling technologies, we are gaining increasing insights into the pathogenesis of disease, prognostic stratification, and potentially actionable sarcoma alterations. Tempus+ has one of the largest comprehensive molecular profiling databases of sarcoma across all histologic subtypes and age ranges. I am just so excited to be able to work with Tempus+ and collaborators across the country to be able to interrogate this enormous annotated resource.””

To read more, click here.

(Source: Business Wire, October 27th, 2022)

Share This Story!